In addition, an RNA Ap specific to Ets1, an oncogenic transcription factor, conjugated to PLGA particles, was shown to increase gefitinib’s anticancer effects specifically in Ets1-overexpressing, gefitinib-resistant H1975 lung cancer cells. The gene discussed is ETS1; the disease is lung cancer.